355sek
-12,3 %
Date:2024-11-22Time:13:14:10Latest report:Q3-2024List:First NorthTicker:ONCOZ
Market Cap:41 msekEnterprise Value:35 msekNet Sales:- msekEarnings:-9,36 msekEmployees:0ISIN:SE0015504097

Ratios

10-year key figure history for OncoZenge turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for OncoZenge with index and moving average MA50 and MA200.

Stockprice:3,59
MA50:7,97
MA200:5,13
Price/MA200:-29,9 %
RSI (14):29,1
Price/MA50:-54,9 %

Description

OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

Pharmaceuticals